US EditionPublished • loading... • Updated
Pfizer faces challenging years on fading COVID sales, ...
- On Tuesday, Pfizer forecast modest 2026 guidance with revenue of $59.5 billion to $62.5 billion and adjusted profit $2.80–$3 per share, while shares were largely flat in premarket trading.
- Amid waning Covid demand, Pfizer cited falling vaccine and Paxlovid sales and pricing concessions from a drug-pricing deal with the Trump administration that compressed margins.
- The company expects a $1.5 billion drop from lower Covid sales and another $1.5 billion from lost exclusivity, with $17 billion potentially affected by patent and regulatory exclusivity expirations in 2026 and 2028.
- Executives will prioritise development spending over buybacks, the company said, exceeding 2025 cost‑saving goals and targeting more than $7 billion in cuts by 2027, mostly by next year.
- In recent years Pfizer has pursued big acquisitions to build future revenue streams, including last month's $10 billion Metsera buy and the $43 billion Seagen tie-up in 2023; Chief Executive Albert Bourla said, 'Vaccines are an essential part of any health care system'.
Insights by Ground AI
39 Articles
39 Articles
In the pandemic Pfizer was the big winner. But now the American drug manufacturer lacks powerful products.
·Zürich, Switzerland
Read Full Article
Coverage Details
Total News Sources39
Leaning Left3Leaning Right4Center9Last UpdatedBias Distribution56% Center
Bias Distribution
- 56% of the sources are Center
56% Center
L 19%
C 56%
R 25%
Factuality
To view factuality data please Upgrade to Premium
